冷沉淀在平衡复苏中如何定位?一项基于黏弹性检测指导复苏的2117例出血患者评估
该研究纳入2017年7月至2021年12月院前或急诊科接受紧急释放血制品的成人创伤患者2117例,排除60分钟内死亡者。冷沉淀输注由到达时及系列黏弹性检测结果决定,计算复苏最初4小时和24小时内红细胞、血浆、血小板及冷沉淀的输注比例,并将接受全血者与仅接受成分输血者比较。总体4小时中位红细胞/血浆/血小板/冷沉淀比例为9:9.5:1.3:1;接受全血者冷沉淀输注时机较晚(10:9.5:1.7:1 vs. 7:6:1:1,p=0.008)。作者认为,使用全血复苏时冷沉淀输注发生更晚;对不使用黏弹性检测而采用算法化复苏方案的中心,应在红细胞/血浆7U后、含全血复苏10U后考虑冷沉淀输注。
要点
- 总体4小时中位红细胞/血浆/血小板/冷沉淀比例为9:9.5:1.3:1(2117例出血创伤患者)。
- 接受全血者冷沉淀输注时机较晚,4小时比例10:9.5:1.7:1 vs. 仅成分输血者7:6:1:1,p=0.008。
- 作者建议:不使用黏弹性检测且采用算法化复苏方案的中心,可在红细胞/血浆7U后考虑冷沉淀输注。
- 作者建议:含全血复苏方案中,可在10U后考虑冷沉淀输注。
- 研究为治疗/临床管理类证据,证据等级III级。
适用人群与场景
- 2017年7月至2021年12月收治的成人创伤患者,院前或急诊科接受紧急释放血制品。
- 排除标准:60分钟内死亡的患者。
- 大量输血患者接受到达时黏弹性检测,并在大量输血方案期间系列复查。
处置流程与药物剂量
- 冷沉淀输注基于黏弹性检测结果决定。
- 大量输血患者到达时行黏弹性检测,并在大量输血方案期间系列复查。
- 每单位全血计为1U红细胞、1U血浆和0.17U血小板。
- 作者建议:不使用黏弹性检测且采用算法化复苏方案的中心,在红细胞/血浆7U后考虑冷沉淀输注。
- 作者建议:含全血复苏方案中,在10U后考虑冷沉淀输注。
研究设计与关键结果
- 研究类型:回顾性评估(基于创伤质量改进项目查询),样本量2117例,人群为成人创伤出血患者。
- 中位年龄37(25,55)岁,男性74%,白人37%,钝性创伤67%,总体生存率77%。
- 总体4小时中位红细胞/血浆/血小板/冷沉淀比例为9:9.5:1.3:1。
- 接受全血者与仅接受成分输血者相比,冷沉淀输注时机较晚:4小时比例10:9.5:1.7:1 vs. 7:6:1:1,p=0.008。
证据类型、等级与局限
- 证据类型:治疗/临床管理类回顾性评估,证据等级III级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 使用黏弹性检测指导复苏时,接受全血的患者冷沉淀输注发生较晚,临床可据此调整冷沉淀启动时机。
- 不使用黏弹性检测而采用算法化复苏方案的中心,作者建议在红细胞/血浆7U后考虑冷沉淀输注。
- 含全血复苏方案中,作者建议在10U后考虑冷沉淀输注。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Empiric cryoprecipitate administration has recently failed to show survival benefit in hemorrhaging trauma patients. However, a recent Trauma Quality Improvement Program query suggested a survival benefit in massive transfusions when administering 1 U of cryoprecipitate to every 7 to 8 U of red blood cells (RBCs). We describe transfusion ratios when cryoprecipitate was indicated by viscoelastic testing (VET) and evaluated whole blood (WB)'s impact on this ratio.
METHODS: Adult trauma patients admitted from July 2017 to December 2021 who received emergency-release blood products prehospital or in the emergency department were included. Patients who died within 60 minutes were excluded. Massive transfusion patients received arrival VET, which was repeated serially while on massive transfusion protocol. Cryoprecipitate transfusion was based on VET results. Blood product ratios were calculated for RBC, plasma, platelets, and cryoprecipitate in the first four and 24 hours of resuscitation. Each WB unit was counted as 1 RBC, 1 plasma, and 0.17 U of platelets. Outcomes were evaluated based on blood component ratios. Patients receiving WB were compared with patients who only received blood components.
RESULTS: A total of 2,117 patients were included. Overall, the median age was 37 (25, 55) years, 74% were male, 37% were white, and 67% sustained blunt trauma. Overall survival was 77%. The median 4-hour RBC/plasma/platelet/cryoprecipitate ratio was 9:9.5:1.3:1. Patients who received WB did not require cryoprecipitate until later in their resuscitation when compared with blood components (10:9.5:1.7:1 vs. 7:6:1:1, p = 0.008).
CONCLUSION: When using routine VET to guide resuscitation for hemorrhage, cryoprecipitate transfusion occurred later in patients receiving WB incorporated resuscitations compared with the component only strategy. For centers that do not use VET and use algorithmic resuscitation protocols, cryoprecipitate transfusion should be considered after 7 U of RBCs/plasma and after 10 U of a WB incorporated resuscitation.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Van Gent JM, Clements TW, Gurney JM, et al. Where does cryoprecipitate fit into balanced resuscitation? An evaluation of 2,117 hemorrhaging patients using viscoelastic-based resuscitation. J Trauma Acute Care Surg. 2025. PMID: 40249632. doi:10.1097/TA.0000000000004643
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。